News

Our news cover the latest topics from the past 30 days, as retrieved from Japanese-language press releases and other information sources.

For older news topics, please use the archive button.

Please use the search module to retrieve information on institutes, researchers and research topics

 

 

14-7 Novo Nordisk takes license from Heartseed Japan for iPS-derived cardiomyocytes

Heartseed has granted Novo the exclusive rights to develop, manufacture, and sell HS-001, regenerated cardiomyocytes derived from heterologous iPS cells in the world except Japan. In Japan, Heartseed will continue to develop the product independently, while retaining the rights to develop, manufacture and market it. After obtaining approval, Heartseed will market the product jointly with Novo’s Japanese subsidiary. License fees may add up to up to 65.5 billion yen (500 million €). In the second half of 2021, HeartSeed plans to start a domestic Phase 1/2 clinical trial (LAPiS trial) for severe heart failure caused by ischemic heart disease as a corporate trial.

Nikkei Biotech news release, July 14, 2021

 

17-2 Kobe University installs „smart cell” pilot lab

In this pilot lab, supported by funds from NEDO; smart cells can be developed in less than one-fifth of the conventional time by combining proprietary long-chain DNA synthesis technology, high-throughput recombination technology, and high-speed, high-precision cell...

read more